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EXPLORING THE ASSOCIATION BETWEEN QUALITY OF LIFE AND 
SURVIVAL IN PATIENTS WITH TRANSTHYRETIN AMYLOIDOSIS 
VICTORIA J. LATTANZI 
ABSTRACT 
Background: Studies in various chronic diseases have correlated health-related quality of 
life (HRQOL) with disease state and treatment outcomes. Limited data exists on the 
association between HRQOL, survival, and clinical biomarkers of disease in wild-type 
and familial TTR amyloidosis (ATTRwt & ATTRm) patient populations.  
 
Objectives: To assess the association between HRQOL and survival, as well as HRQOL 
and clinical biomarkers of disease in transthyretin-mediated amyloidosis (ATTR) patient 
populations.  
 
Methods: Using a retrospective cohort study design, HRQOL was assessed via SF-36 
health surveys collected from patients with ATTRwt and ATTRm presenting for their 
initial evaluation at the BU Amyloidosis Center between 1985 and 2015. Kaplan-Meier 
curves and hazard ratios (HRs) calculated using Cox proportional hazards regression 
analysis were used to examine the association between physical (PCS) and mental (MCS) 
component scores derived from the SF-36 health surveys and survival follow-up. All 
analyses were adjusted for potential confounders such as age at presentation, gender, and 
co-morbidities including diabetes mellitus, hypertension and hyperlipidemia. Spearman’s 
rank correlations were calculated to assess the association between PCS, MCS and 
  vii 
clinical biomarkers of disease (mBMI, troponin I and BNP) also collected at time of 
initial evaluation visit. Statistical significance was set at a two-sided alpha=0.05. 
 
Results: In the ATTRwt cohort, 133 white males, aged 74.6 + 6.0 years (mean + SD) 
presented with mean MCS (45.7 + 12.3) and PCS (36.7 + 10.8) that were respectively, 
0.5 and 1.5 SD below 50. Patients with PCS or MCS scores < 35 had a significantly 
higher risk of death during follow-up than those with scores > 35 for PCS (HR=2.45; 
p=0.002) and for MCS (HR=3.38, p<0.0001). BNP and troponin I associated with MCS 
(r= - 0.24; p=0.01 and p=0.02, respectively) and PCS (r= - 0.29; p=0.002 and r= - 0.25; 
p=0.012, respectively). In the ATTRm cohort, 331 white (82%) males (67%), aged 57.5 + 
13.9 years presented with mean MCS (45.2 + 11.7) and PCS (37.2 + 13.3). Patients with 
PCS scores < 35 had a significantly higher risk of death during follow-up than those with 
scores > 35 (HR=2.76; p= <0.0001). In contrast, MCS scores < 35 did not correlate with 
increased risk of death during follow-up (HR=1.38, p=0.13). BNP and troponin I most 
strongly associated with PCS (r= - 0.50; p<0.0001 and r= - 0.41; p<0.0001, respectively) 
and less with MCS (r= - 0.16; p=0.03 and r= - 0.24; p=0.007, respectively). mBMI did 
not associate with MCS or PCS in the ATTRwt and ATTRm cohorts.  
 
Conclusions: ATTR disease significantly decreased an individual’s physical and mental 
HRQOL. PCS and MCS were shown to be independent predictors of mortality but their 
ability to predict survival varied by cohort. Assessment of HRQOL may provide valuable 
prognostic information that could be of use in the management of ATTR disease.  
  viii 
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SECTION 1. INTRODUCTION 
 
1.1 Amyloidosis 
 
Amyloidosis represents a group of disease states caused by the misfolding and 
accumulation of proteins. The folded structure of a protein, known as its native state 
dictates its function. When a protein is misfolded it is unable to carry out its highly 
specialized biological role and must be cleared from the body (Figure 1).1 Typically, 
misfolded protein removal is achieved through proteasomal degradative pathways as part 
of normal cellular processes.2  However, failure to remove aberrantly folded proteins 
triggers a multi-step self-assembly pathway where build-up of misfolded protein results 
in the development of large molecular aggregates.3-4 These aggregates continue to 
accumulate into insoluable amyloid fibrils that can deposit into various organs and tissue 
types, causing progressive disruption of normal organ and tissue function.5-6  
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Figure 1. Protein Folding, Misfolding and Aggregation  
When a protein is unable to maintain its native state, misfolded proteins are degraded and 
cleared from the body. However, if degradation does not occur, misfolded proteins 
accumulate, aggregate and deposit as amyloid fibrils in organs and tissue. 
 
 
Source: Tyedmers J, Mogk A and Bukau B. Cellular strategies for controlling protein 
aggregation. Nature Reviews Molecular Cell Biology. 2010;11:777-788. Reproduced 
with permission from Nature Publishing Group. 
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To date, approximately 30 proteins have been shown to have misfolding capabilities that 
result in specific amyloidotic disease states.7 The clinical manifestations of amyloid 
disease are dependent on the protein type involved and the target organ or tissue. 
Alzheimer’s disease (AD) and Parkinson’s disease (PD) are examples of well-known 
amyloidotic diseases hallmarked by progressive neurodegeneration in the brain.8 Both are 
considered forms of localized amyloidoses as they involve amyloid fibril deposition 
exclusively in one organ. There are also 4 major systemic amyloidoses that involve the 
deposition of specific proteins and affect multiple organs. Amyloid light-chain (AL) 
amyloidosis is the most common type, caused by the accumulation of misfolded 
immunoglobulin light chain proteins. Approximately 4,000 new cases are diagnosed 
annually in the US, most frequently affecting the kidney and the heart.9-10 Amyloid A 
(AA) amyloidosis results from the deposition of serum amyloid A (SAA) protein 
aggregates and is secondarily associated with inflammatory diseases such as rheumatoid 
arthritis and chronic infection.11-12 The remaining 2 major forms of systemic amyloidosis 
involve deposition of normal and genetically mutated transthyretin (TTR) protein in 
various organs and tissues.13-14 
 
Regardless of etiology or pathology, amyloidoses are rare diseases affecting populations 
worldwide.13 In the United States, they are estimated to affect less than 200,000 people 
total and have been granted orphan disease designation by the National Institute of Health 
(NIH).15-17 However, it is possible that amyloidoses are not truly rare, but rarely 
diagnosed due to a lack of disease awareness.18 In addition to the advancing disease 
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treatment options, current research initiatives aim to better educate the general and 
medical communities on disease risk factors and common disease symptoms. It is hoped 
that increased awareness will lead to early diagnosis, more effective management of 
disease, and ultimately, improved disease prognosis. As part of this disease awareness 
initiative, attention should also be directed toward better understanding how patient 
perception of health can serve as a measure of disease extent. Determining this 
association is of particular interest in patient populations with TTR-mediated 
amyloidosis, as they have limited effective treatment options available. 
 
1.2 Transthyretin-mediated Amyloidosis 
 
Transthyretin-mediated amyloidosis (ATTR) is a progressively debilitating disease at 
both the organ and functional level resulting in death due to the systemic aggregation of 
misfolded transthyretin (TTR) protein.6,19,48 Biologically, TTR protein is produced 
predominantly by the liver and transports vitamin A and thyroid hormone throughout the 
body.14 TTR circulates as a tetramer comprised of 4 monomeric subunits. If 
destabilization of the tetramer occurs, the monomeric subunits dissociate, misfold and 
aggregate as amyloid fibril deposits (Figure 2).20 There are two major categories of 
ATTR: wild-type TTR (ATTRwt) and familial ATTR (ATTRm). ATTRwt results from 
the destabilization, misfolding and deposition of normal TTR.21-23 Conversely, ATTRm 
results from specific point mutations in the TTR gene conferring one amino acid 
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substitution that destabilizes the tetramer, promoting misfolding and misaggregation of 
the monomeric subunits.20,24-26  
 
Figure 2. Overview of TTR Amyloidogenesis 
Dissociation of the functional TTR tetramer results in misfolding of monomeric subunits. 
Subsequent accumulation and aggregation of misfolded monomers result in the 
deposition of TTR amyloid deposits throughout the body. 
 
 
Source: Eisele YS, Monteiro C, Fearns C, et al. Targeting protein aggregation for the 
treatment of degenerative diseases. Nature Reviews Drug Discovery. 2015;14(11):759-
780. Reproduced with permission from Nature Publishing Group. 
 
1.3 Clinical Presentation of Wild-type Transthyretin-mediated Amyloidosis 
 
Wild-type Transthyretin-mediated Amyloidosis (ATTRwt) predominantly targets the 
heart. It is a sporadically acquired disease, typically affecting elderly males and is often 
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referred to as age-related or senile systemic amyloidosis (SSA).27 Although extensive 
prevalence studies have not been conducted, ATTRwt is considered the most common 
systemic form of amyloidosis based on autopsy studies.28 Disease onset is reported to 
occur after 60 years of age, but predominately affects those in their eighth and ninth 
decade of life.14,29 The diagnosis is often overlooked due to the older patient population 
often experiencing multiple age-related system declines.10,30 The most commonly 
reported clinical symptoms include cardiomyopathy, heart failure, atrial fibrillation, and 
conduction disturbances.26,28 
 
1.4 Clinical Presentation of Familial Transthyretin-mediated Amyloidosis  
 
Familial Transthyretin-mediated Amyloidosis (ATTRm) is the most common heritable 
form of amyloidosis. It is caused by autosomal dominant inheritance of specific TTR 
genetic mutations.31 To date, there are over 120 TTR mutations reported, most of which 
result in symptomatic amyloid disease, predominantly in males.32 It is estimated that 
ATTRm affects 1 in 100,000 individuals in the United States.10 On average, ATTRm 
patients will experience symptomatic onset at approximately 50 to 60 years of age. 
However, ATTRm has been reported as early as age 20 for aggressive mutations and as 
late as 90 years of age for those with milder, later onset mutations.33-35 Overall, the 
specific underlying TTR mutation and environmental influences will dictate disease age 
of onset and clinical manifestations.  
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TTR Val30Met is one of the most common mutations worldwide. It is largely associated 
with neuropathy due to progressive dysfunction of the peripheral and autonomic nervous 
systems.36 Cardiac disease activity is also seen in those with late stage disease. While first 
described in Portugal, other endemic foci of the TTR Val30Met mutation have been 
found throughout Sweden, Brazil, Europe, Japan and the United States.14,37 Interestingly, 
age of disease onset will vary based the specific geographic origin of the Val30Met 
mutation. For example, symptomatic age of onset for TTR Val30Met mutation endemic 
to Portugal and Japan is 30-40 years of age in contrast to 50-60 years of age for 
Val30Met mutations endemic to Sweden.14,25,38 The reason for such variation in age of 
onset is unknown, but serves to highlight the complexities that must be considered when 
diagnosing and treating ATTRm disease.  
 
Other commonly reported TTR mutations include, Val122Ile, Ile68Leu, Thr60Ala and 
Leu111Met. These mutations largely affect the heart, but not exclusively. The TTR 
Val122Ile is of particular interest as it is almost exclusively found in African American 
populations. More specifically, it is found in 3.9% of the African American male 
population, in contrast to Caucasian and Hispanic populations where it affects 0.44% and 
0%, respectively.39 TTR Thr60Ala, Ile68Leu and Leu111Met are all associated with late 
onset disease hallmarked by cardiac involvement endemic to different geographic 
regions. Thr60Ala is most commonly seen in populations of Irish descent, whereas 
Ile68Leu and Leu111Met largely affect Danish and Northern Italian populations, 
respectively.26,40-41 
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1.5 Prognosis & Diagnosis of ATTR 
 
All ATTR-mediated organ damage caused by protein deposition is irreversible and no 
specific therapy exists to eliminate existing deposits. Consequently, early disease 
detection and management is needed to achieve the best possible clinical outcomes. 
Unfortunately, it is not uncommon for patients to have active disease long before the 
clinical diagnosis of amyloidosis is made.6 In the ATTRm population, the average time 
from symptom onset to diagnosis of amyloid cardiomyopathy is 22 months, and 30 
months for those with peripheral neuropathy.42 Diagnoses made in late stages of both 
ATTRm and ATTRwt disease often correlate with poor outcomes as treatment is 
ineffective or impossible due to extensive organ involvement and damage. On average, 
ATTRm survival is 10 years from time of symptomatic onset of peripheral nerve 
dysfunction.14,19 However, survival prognosis can vary by organ involvement and 
mutation type where those with more aggressive mutations or more extensive organ 
involvement experience earlier death. Due to this variability, without intervention, 
ATTRm survival can range from 5 to 15 years from time of symptomatic onset.  6, 35, 43 In 
patients presenting with significant heart involvement, survival from time of diagnosis is 
as low as 2 years in the ATTRm population and ranges from 2 to 6 years in the ATTRwt 
population. 44-45, 89-90 
 
ATTR diagnosis requires pathologic evidence of amyloid deposits in any tissue. Tissue 
collected from any source is stained with Congo red, which displays apple green 
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birefringence in the presence of amyloid deposits under polarized light.6,19 
Immunohistochemical staining of tissue with antibodies specific to known amyloidogenic 
proteins or mass spectrometry are used to identify the type the amyloid present.26 In 
addition to identifying the specific amyloid proteins present, genetic sequencing is also 
performed to determine the specific mutation present if ATTRm or to confirm the 
presence of wild-type sequence, if ATTRwt. Figure 3 displays examples of these 
routinely used diagnostic assays.19   
 
Figure 3. Diagnostic Assays Used to Classify the Type of TTR Amyloid Present  
(A-C) Light microscopy images of duodenum biopsy tissue from a patient with Val30Met 
TTR histochemically prepared with: (A) Congo red staining, where presence of red stain 
indicates amyloid deposit, (B) Congo red staining under polarized light, demonstrating 
signature amyloid protein apple green birefringence and (C) immunohistochemistry 
staining with an anti-TTR antibody. The scale bar represents 200 µm. (D-E) Genetic and 
proteomic based assays show (D) Genetic sequencing analysis of the TTR gene, 
revealing the Val30Met TTR mutation and (E) Mass spectrometry analysis of serum from 
a patient with Val30Met TTR. Presence of Val30Met TTR mutation is evidenced by a 
peak shift reflective of a difference in the molecular weight detected. (Note: the 
molecular weight of Val30Met TTR is known to be 32 m/z higher than the molecular 
weight of WT TTR).19 
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Source: Ueda M, Ando Y. Recent Advances in transthyretin amyloidosis therapy. 
Translational Neurodegeneration.2014;3:19. 
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1.6 Clinical Management of ATTR 
 
Current clinical management of ATTR involves symptomatic treatment of end-organ 
disease as well as various interventions aimed to stabilize and/or eliminate TTR. In the 
ATTRm population, early liver transplantation has been shown to successfully eliminate 
the production of amyloidotic TTR precursors preventing further amyloid formation.35 
Heart transplantation is also a plausible treatment option, but only for those with severe 
cardiac disease as it carries significant risk of complication.6 Other treatments include 
diflunisal, a non-steroidal, anti-inflammatory TTR tetramer stabilizing agent, as well as 
gene-silencing drug therapies currently in clinical trials, which inhibit TTR production at 
the RNA level.47-48 While the interventions mentioned above have shown to demonstrate 
the most promise in halting disease progression, Figure 4 provides an overview of the 
current treatment landscape, including all conventional and investigational treatment 
options along with their therapeutic targets.19 Overall, the most appropriate disease 
management plan varies based on organ involvement at time of presentation. The ability 
to quantify disease-mediated organ involvement typically involves the assessment of 
well-characterized clinical biomarkers of disease.  
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Figure 4. Conventional and Investigational Treatment Options for TTR 
Amyloidosis 
This schematic shows the various TTR amyloidosis treatment options and their 
therapeutic targets. The aim is to slow disease progression by altering various stages of 
the TTR production pathway.  
 
 
Source: Ueda M, Ando Y. Recent Advances in transthyretin amyloidosis therapy. 
Translational Neurodegeneration. 2014;3:19. 
 
 
 
 
 
  
 13 
1.7 ATTR Biomarkers of Disease 
 
Cardiac biomarkers such as troponin I and B-type natriuretic peptide (BNP) are routinely 
measured to assess the level of heart muscle injury and ventricle pressure overload, 
respectively.49-50 These diagnostic measures of ATTR cardiac involvement have been 
shown to predict survival in ATTRwt patients.21-22 Other clinical biomarkers of ATTR 
disease include modified body mass index (mBMI), a measure of nutritional status. 
Interestingly, in the ATTRm population, mBMI has been shown to correlate with survival 
in the context of mortality post liver transplantation. ATTRm patients with higher mBMI 
experience better survival outcomes.51-52 Since these cardiac and nutritional biomarkers 
offer insights into overall organ dysfunction and survival, they are often the primary 
measures used to define health status and direct disease management decisions. As organ 
involvement progresses, ATTRwt and ATTRm patients will experience significant 
disease-related impact on their daily functioning, both physically and mentally. 
Understanding how progressive functional debilitation impacts health-related quality of 
life (HRQOL) is an area of study that warrants further investigation, as it is possible that 
patient-reported health status could impact disease outcome in ways not previously 
considered in the ATTR patient population. 
 
 
 
  
 14 
1.8 Quality of Life in Other Disease Areas 
 
Patient-reported HRQOL has become a powerful prognostic measure of disease outcome 
in many diseases. One of the most widely used measures of HRQOL is a validated, self-
administered health status questionnaire called the 36 question short form (SF-36) health 
survey instrument. The SF-36 health survey was one of several health survey instruments 
developed to assess self-perceived health status as part of the Medical Outcomes Study 
(MOS), a longitudinal, observational study examining the effects of variable physician 
care models on patient outcomes.53 This study emphasized the clinical importance of 
gaining patient perspectives on general health, suggesting that a HRQOL health survey 
could be just as valuable as biological markers of disease when assessing survival and 
treatment efficacy.54  
 
The SF-36 health survey is a short-form which means that it is able to assess functional 
health status with fewer questions compared to its long-form counterparts. This 
distinction reduces the burden placed on the individual completing the questionnaire, 
thereby making it more accessible to a diverse patient population. While one might think 
that fewer questions would reduce the precision of a health survey, when evaluated in 
adequate sample sizes, the SF-36 health survey has been validated to reliably capture 
HRQOL differences between groups.53 It is comprised of 36 specific questions designed 
to provide a comprehensive assessment of overall HRQOL as categorized by 8 scales 
defining important health domains that affect aspects of everyday living. These 8 scales 
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include physical functioning (PF), role limiting physical problems (RP), bodily pain (BP), 
general health (GH), social functioning (SF), mental health (MH), role limiting emotional 
problems (RE), and vitality (VT). These scales further aggregate into summary measures 
that describe physical and mental health status, expressed as a physical component 
summary (PCS) and mental component summary (MCS) scores, respectively. Scales 
contributing to PCS include PF, RP, BP, and GH whereas SF, MH, RE, and VT 
contribute to the MCS.54-55 Figure 5 provides an overview of how each of the 36 health 
survey questions contributes to the overall PCS and MCS.56  
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Figure 5. Description of SF-36 Health Survey Measurement Model 
This schematic provides an overview of how each SF-36 health survey question (item) 
contributes to the overall PCS and MCS (summary measures). 
 
Source: Derraik JGB, deBock M, Hofman PL, Cutfield WS. Increasing BMI is associated 
with progressive reduction in physical quality of life among overweight middle-aged. 
Scientific Reports.2014;4:3677.  
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The ability to distinguish between physical and mental health status afforded by the SF-
36 health survey is useful when examining health outcomes within a population. This is 
particularly relevant in the context of disease as it is possible for physical and mental 
health effects to vary in a disease-dependent manner. Overall, given its ease of 
administration and ability to gather meaningful health status data, the SF-36 health 
survey continues to be used as a clinical supplement to assess disease burden and patient 
prognosis in populations with chronic disease.  
 
In various chronic diseases, SF-36 health survey data have been utilized to assess survival 
outcomes. In an observational study examining HRQOL and survival in patients with 
head and neck cancer, mean PCS (42.3 + 10.9) and MCS (44.7 + 12.2) were reported to 
be approximately 0.5 to 1 SD below the US population norm of 50. PCS significantly 
associated with survival (HR=0.86; 95% CI 0.80 to 0.93) in such a manner that every 5-
unit increase in PCS associated with an 0.14 times lower risk of death. Comparable 
deficits in MCS did not significantly associate with mortality.58 Similar findings have 
been reported in patients with chronic liver disease where only low PCS significantly 
associated with increased risk of death (p<0.0001).59  
 
A prospective population-based cohort study examining HRQOL changes following lung 
cancer surgery showed that both MCS and PCS significantly associated with survival 
over time. Baseline mean MCS and PCS were reported as 39 + 13 and 47+11, 
respectively. At baseline, only PCS significantly associated with survival (HR=0.958; 
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p=0.003). However, at 6-month follow-up, a 10% decrease in MCS (HR=0.82; p=0.033) 
and PCS (HR=0.87; p=0.014) associated with an 18% and 13% higher risk of death, 
respectively.91 
 
In patients with chronic kidney disease undergoing hemodialysis, both mental and 
physical HRQOL deficits were independently associated with increased mortality. As 
part of 1-year survival analysis, patients with scores less than 30 for both MCS 
(HR=1.48; 95% CI 1.32 to 1.64) and PCS (HR= 1.62; 95% CI 1.36 to 1.92), experienced 
the greatest risk of death when compared to US population norm of 50 or more.60 
Another study evaluating HRQOL in patients with chronic kidney disease also showed 
that lower PCS and MCS scores associated with significantly poorer survival. As such, 
each 10-unit decrease in PCS (HR=1.12; p<0.001) and MCS (HR=1.08; p<0.001) 
associated with a greater risk of death. Interestingly, within the African-American subset 
of the overall population, only MCS deficits were able to predict survival (HR=1.10, 
p<0.001). In addition to examining the relationship between HRQOL and mortality, this 
study also showed that lower HRQOL as reported by the SF-36 health survey associates 
with protein energy wasting status by serum albumin and creatinine levels, both disease-
specific clinical biomarkers of disease.61  
 
While disease pathology may differ, these studies demonstrate an intriguing relationship 
between HRQOL, survival and clinical biomarkers of disease that could be of clinical 
value. This relationship suggests that HRQOL is an important metric of functional health 
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status that should be considered when evaluating the overall health of patients with 
chronic disease. The variability shown by these studies in how HRQOL associates with 
survival in different diseases, suggests that generalizations should not be made and 
applied across chronic disease states. Accordingly, HRQOL and survival assessments 
should be conducted in a disease-specific manner in order to gain a better understanding 
of how physical and/or mental deficits affect overall health outcomes within a population 
of interest. The information gained from such disease-specific study could guide more 
effective disease management decisions and lead to improved patient outcomes.  
 
1.9 Quality of Life in Amyloidosis 
 
No data to date examine the specific relationship between HRQOL and survival in the 
ATTR patient population. The current data suggest that ATTR patients with the greatest 
disease burden report the poorest quality of life as measured by the SF-36 health 
survey.62 However, it is unclear how the self-perceived assessment of physical and mental 
functioning, represented as PCS and MCS, relates to disease prognosis in this patient 
population. While studies in ATTRm and light-chain amyloidosis (AL) have shown 
correlations between HRQOL, disease progression, and treatment outcomes, respectively, 
they do not examine HRQOL and survival in a context representative of the greater 
ATTR patient population.47,63 
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For patients with ATTR, the lack of curative treatments coupled with the irreversible 
functional decline due to disease-related organ damage make timely and thorough disease 
management planning imperative. Understanding how HRQOL, specifically physical and 
mental health status, relates to survival and clinical biomarkers of disease could have 
clinical value in that it might potentially help predict disease outcomes more effectively 
for this specific population. The ability to better predict disease outcomes may have 
clinical significance as it could help guide individualized disease management plans that 
may ultimately lead to improved survival.  
 
1.10 Boston University Amyloidosis Center 
 
As TTR amyloidoses are complex diseases involving multiple organ systems, clinical 
management requires a multidisciplinary approach.  Specialized treatment and research 
centers exist worldwide to provide diagnostic evaluation and disease-specific treatment 
options. Boston University (BU) Amyloidosis Center is an internationally recognized 
leader in amyloidosis research and patient care. The Center follows hundreds of ATTRwt 
and ATTRm patients from all over the world. At initial presentation to the Center, 
patients undergo an extensive evaluation process, often involving full neurological, 
cardiac and genetic workups to assess disease state. Also, as part of this process, patients 
complete a SF-36 health survey to determine their self-perceived assessment of mental 
and physical status. SF-36 health surveys are also collected at annual follow-up visits.  
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Clinical information collected at all visits is stored in a patient database and, with patient 
consent, can be used for research purposes. Specific information captured in this database 
include patient diagnosis, biopsy status, clinical involvement, SF-36 health survey, as 
well as clinical biomarkers of disease. The extensive clinical information collected in this 
database on such a large patient population, makes it an ideal source of data to examine 
the relationship between HRQOL and survival in the TTR population.  
 
1.11 Study Rationale 
 
Upon review of HRQOL studies in other disease areas it is clear that patient-reported 
health status has meaningful implications on patient outcomes. Given the progressively 
debilitating disease course and limited treatment options for patients with ATTR, 
understanding how HRQOL relates to overall health outcomes, particularly survival 
warrants investigation. To date there has been no formal evaluation of this relationship in 
the TTR amyloidosis community. As a world renowned amyloid center of excellence 
following a large cohort of both ATTRm and ATTRwt patients, the BU Amyloidosis 
Center systematically collects SF-36 health surveys as part of Center’s clinical evaluation 
process. It is possible that HRQOL is an important metric of functional health that could 
help predict disease outcomes. It is also possible that functional health varies by TTR 
disease type. For this reason, studying how disease status relates to functional health in 
both ATTRm and ATTRwt patients could be of clinical significance in that it could guide 
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individualized disease management plans that may ultimately lead to improved survival 
in the overall ATTR patient population.  
 
1.12 Purpose 
 
The purpose of this research is to determine the association between HRQOL, clinical 
biomarkers of disease, and survival in the ATTR patient population followed by the BU 
Amyloidosis Center.  
 
1.13 Study Questions 
 
1. Primary Study Question: Is HRQOL status predictive of survival in the ATTR patient 
population at presentation to the BU Amyloidosis Center?  
 
2. Secondary Study Question: Do clinical biomarkers of disease (troponin I, BNP, 
mBMI) correlate with HRQOL status in the ATTR population at presentation to the 
BU Amyloidosis Center? 
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1.14 Study Objectives 
 
1. Primary Objective: Determine the association between SF-36 health survey scores 
and relative risk of death for patients upon presentation to the BU Amyloidosis 
Center. 
 
2. Secondary Objective: Evaluate the relationship between clinical biomarkers of 
disease (troponin I, BNP, mBMI) and SF-36 health survey scores for patients upon 
presentation to the BU Amyloidosis Center. 
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SECTION 2. MATERIALS & METHODS 
2.1 Study Design 
 
To determine the association between HRQOL and survival in the BU Amyloidosis 
ATTR patient population, a retrospective cohort study was conducted (Figure 7). The 
two study cohorts were comprised of individuals diagnosed with ATTRwt or ATTRm 
who, as part of their initial evaluation visit occurring between 1985 and 2015, completed 
a SF-36 health survey and had corresponding clinical biomarkers of disease measures 
recorded in the BU Amyloidosis Center database. Exposure was defined as completion of 
a SF-36 health survey at time of initial BU Amyloid Center evaluation visit. SF-36 health 
survey raw scores for each of the 8 subscales defining health status were further grouped 
and expressed as physical (PCS) and mental (MCS) summary scores. US healthy 
population norms, standardized with respect to age and gender were used as controls for 
evaluating PCS and MCS in both cohorts. In order to determine survival, the study 
outcome of interest, follow-up data was obtained for individuals in both cohorts. Survival 
follow-up started at time of SF-36 health survey completion and continued until date of 
death, or end of study period. Those without a date of death recorded between 1985 and 
2015 were considered alive for the purpose of survival analyses. 
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Figure 6. Study Design Diagram 
 
 
 
2.2 Patient Population  
 
The BU Amyloidosis Center database was queried to identify ATTRwt and ATTRm 
patients who completed SF-36 health surveys at their initial evaluation visit between 
1985 (year when SF-36 health surveys were first introduced to Center) and 2015 (year of 
data extraction for study analysis). Demographic information collected included sex, 
gender, and race. To determine survival, date of birth and death were also collected for all 
those included in the study. Disease-specific data collected included presence of wild-
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type versus genetic mutation, date of presentation visit, date of diagnosis, co-morbidities 
and measures of known clinical biomarkers of disease (mBMI, troponin I and BNP). 
 
Inclusion Criteria 
• Individuals diagnosed with ATTR (ATTRwt or ATTRm) as confirmed by 
amyloid tissue typing and TTR gene sequencing who presented to the BU 
Amyloidosis Center between 1985 and 2015 for their initial evaluation visit, and 
who: 
• had completed at least one SF-36 health survey as part of their initial evaluation 
visit, and 
• had corresponding clinical disease measures (co-morbidities, mBMI, troponin I 
and/or BNP) obtained at time of SF-36 health survey completion recorded in the 
BU Amyloidosis Center’s database. 
 
Exclusion Criteria 
• Individuals without confirmed ATTR diagnosis by amyloid tissue typing and TTR 
gene sequencing between 1985 and 2015, and/or 
• did not complete at least one SF-36 health survey as part of their initial evaluation 
visit, and/or 
• did not have corresponding clinical disease measures (co-morbidities, mBMI, 
troponin I and/or BNP) obtained at time of SF-36 health survey completion 
recorded in the BU Amyloidosis Center database. 
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2.3 Institutional Review Board Approval 
 
Prior to the initiation of any study activity, institutional review board (IRB) approval was 
obtained from the Boston University Medical Campus IRB (BUMC IRB). BUMC IRB 
approval (H-22838) allowed for de-identified patient data extraction from the BU 
Amyloidosis Center database. The de-identification process involved generation of 
unique identification numbers for each patient included in the study analysis.  
 
2.4 The 36 Question Short Form (SF-36) Health Survey Instrument 
 
The SF-36 health survey instrument is a validated, self-administered questionnaire that 
captures both physical and mental health status through 36 questions categorized into 8 
subscales: physical functioning (PF), role limiting physical problems (RP), bodily pain 
(BP), general health (GH), social functioning (SF), mental health (MH), role limiting 
emotional problems (RE), and vitality (VT). For statistical analyses, these 8 scales were 
further classified into two health status summaries known as the physical component 
score (PCS) and mental component score (MCS) according to the SF-36 Health Survey 
Manual and Interpretation Guide. Scales contributing to PCS included PF, RP, BP, and 
GH whereas SF, MH, RE, and VT contributed to the MCS.55 PCS and MCS summary 
scores were used as measures of HRQOL for all those included in the study.  
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2.5 Statistical Analysis 
 
To obtain PCS and MCS summary scores, the 8 subscale scores were first calculated by 
adding together subscale-related raw scores recorded for each individual item on the SF-
36 health survey. Z-score transformations allowed for conversion of each subscale to a 0 
to 100 scoring scale, where 0 is equal to poorest health status and 100 is equal to highest 
or best possible health status. Subscale scores were aggregated and standardized using 
physical and mental scoring coefficients, and means and standard deviations from the 
general US population. The resulting PCS and MCS summary scores were then adjusted 
for age and gender against US adult population norms, which were used as healthy 
controls. A PCS or MCS score of 50 indicated an average HRQOL status, while a PCS or 
MCS score less than 50 will represent a below average HRQOL status. In order to detect 
the greatest risk possible, PCS and MCS were dichotomized 1.5 standard deviations 
below the US population mean of 50 for both PCS and MCS summary scores (< 35 vs. > 
35). For missing SF-36 health survey responses, a representative subscale average was 
determined and imputed to allow each eligible patient to be included in analyses. 
 
In both cohorts, exposure was defined as completion of SF-36 health survey at time of 
presentation to BU Amyloidosis Center. All individuals underwent survival follow-up 
until death occurred, the outcome used to assess survival. Survival was defined as the 
time from presentation to the BU Amyloidosis Center to death by any cause. As part of 
Cox proportional regression analyses, the relative risk of death associated with PCS and 
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MCS summary scores was assessed using hazard ratios (HR) by cohort. During the 
follow-up period examined, death by any cause was considered an event, and those alive 
at time of last follow-up or at the end of the study period were censored for the purpose 
of survival analyses. Additionally, all analyses were adjusted for potential confounders 
such as age at presentation, gender, and co-morbidities including diabetes mellitus, 
hypertension and hyperlipidemia. The Kaplan-Meier method was used to create survival 
curves to assess the distribution of death by PCS and MCS < 35 vs. > 35 during study 
follow-up. As part of a secondary analysis, Spearman’s rank correlations were also 
calculated to describe the association between PCS and MCS and clinical biomarkers of 
disease such as mBMI, troponin I and BNP. For all analyses, statistical significance was 
set at a two-sided alpha=0.05. 
 
Statistical Analysis Software (SAS) was used for all data manipulation and statistical 
analyses.  
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SECTION 3. RESULTS 
 
During the study period, 464 individuals diagnosed with either ATTRwt (n=133) or 
ATTRm (n=331), were identified as having completed a SF-36 health survey at time of 
presentation to the BU Amyloidosis Center. Baseline characteristics of both cohorts are 
presented in Table 1.  
 
Overall, at time of SF-36 health survey completion, both cohorts were predominantly 
comprised of white males in their seventh to eighth decade of life. In the ATTRwt cohort 
(n=133), the mean age + SD was 74.6 + 6.0 years; 100% were males, and 100% were 
white. The ATTRm cohort (n=331) was significantly younger, with a mean age + SD of 
57.5 + 13.9 years, and more diverse with 33% female, and 82% white. The most common 
genetic mutations in the ATTRm cohort were Thr60Ala (22%, n=74), Val30Met (19%; 
n=64) and Val122Ile (13%; n=44). The ATTRwt cohort, by definition, had no genetic 
TTR mutations. These cohorts were representative of the general ATTR population based 
on previously defined disease demographics. 
 
Of the co-morbidities examined, 40% of the ATTRwt population presented with 
hyperlipidemia. Although hyperlipidemia was the most prevalent co-morbidity within the 
ATTRwt cohort, its presentation was not significantly different between the two cohorts 
(p=0.22).  Within the ATTRm cohort, 47% presented with hypertension, which was 
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significantly greater than in the ATTRwt cohort where only 14% were affected 
(p<0.0001).  
 
Clinical biomarkers assessed at the time of SF-36 health survey completion include 
modified BMI, troponin I and BNP for both cohorts. In the ATTRwt cohort, troponin I 
and BNP mean values (0.17 ng/mL; n=102 and 427.9 pg/mL; n=118, respectively) were 
significantly higher than those of the ATTRm cohort (0.08 ng/mL; n=130 and 241.9 
pg/mL; n=179, respectively) as indicated by the respective p-values of p=0.002 and 
p<0.0001. Mean modified BMI was also higher in the ATTRwt cohort (1181.6; n=116) 
when compared to the ATTRm cohort (1114.3; n=149), but not to the same level of 
significance as troponin I and BNP (p-value=0.02). In both cohorts, not all individuals 
had complete clinical biomarker data entered in the Center’s database. Therefore, the 
mean values calculated for clinical biomarkers of interest were based on a subset of each 
cohort population that had data recorded in the database at time of SF-36 health survey 
completion. 
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Table 1. Comparison of demographic and clinical features for ATTRwt & ATTRm 
cohorts at time of the SF-36 health survey completion 
  
Feature ATTRwt (n=133) 
ATTRm 
(n=331) p-value 
Age, y mean (SD) 74.6 (6.0) 57.5 (13.9) < 0.0001 
Age, %    
20-40 years 0% 15% < 0.0001 
41-60 years 1 35 
61-80 years 86 48 
> 81 years 13 2 
Sex, %    
Male 100% 67% -- 
Female 0 33 
Race, %    
White 100% 82% -- 
Black/African American 0 14 
Asian 0 3 
Otheri 0 1 
Mutation Type (%)    
Thr60Ala (n=74) -- 22% -- 
Val30Met (n=64) 19 
Val122Ile (n=44) 13 
Lys58His (n=38) 11 
Ser77Tyr (n=15) 5 
Other (n=91) 27 
Unknown (n=5) 2 
Co-Morbidities, %    
HL 40% 32% 0.12 
DM 11 8 0.22 
HTN 14 47 < 0.0001 
Clinical Assessments, 
mean (SD, N) 
    
Modified BMI 1181.6 (188.9; n=116) 1114.3 (264.5; n=149) 0.02 
Troponin I (ng/mL) 0.17 (0.25; n=102) 0.08 (0.15; n=130) 0.002 
BNP (pg/mL) 427.9 (298.6; n=118) 241.9 (403.3l; n=179) < 0.0001 
iincludes > 1 race, Unknown 
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Table 2 presents standardized PCS and MCS values showing that individuals reported 
lower PCS compared to MCS on average for both cohorts. For the ATTRwt cohort, the 
mean PCS and MCS scores were 36.7 + 10.8 and 45.7 + 12.3, respectively. Whereas, the 
mean PCS and MCS scores for the ATTRm cohort were 37.2 + 13.3 and 45.2 + 11.7, 
respectively. The lowest PCS value reported in the ATTRwt cohort was 12.5 and 7.5 in 
the ATTRm cohort. For the MCS, the lowest values reported was 16.5 in the ATTRwt 
and 12.3 in the ATTRm cohort. Conversely, the highest PCS reported was 57.9 in the 
ATTRwt population and 64.9 in the ATTRm cohort. The highest MCS value reported for 
the ATTRwt was 72.5 and 71.9 for the ATTRm cohort. Collectively, the range of PCS 
and MCS observed further demonstrates that individuals experienced lower PCS relative 
to MCS, which reflects poorer physical health status, even when considering the highest 
and lowest scores in both cohorts.  
 
Table 2. Presentation of PCS and MCS scores in ATTRwt & ATTRm cohorts 
SF-36 Component Score Mean SD Min Max 
ATTRwt Cohort (n=133)     
PCS 36.7 10.8 12.5 57.9 
MCS 45.7 12.3 16.5 72.5 
ATTRm Cohort (n=331)     
PCS 37.2 13.3 7.5 64.5 
MCS 45.2 11.7 12.3 71.9 
 
Survival characteristics and PCS and MCS scores (< 35 vs. > 35) by cohort are presented 
in Table 3. During the follow-up period, 54% (n=72) of the ATTRwt and 36% (n=120) 
of the ATTRm population died. Mean survival time from completion of SF-36 health 
survey within the ATTRwt was 3.0 + 2.2 years. This was less than mean survival time 
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observed for the ATTRm cohort of 6.4 + 5.4 years. Time-to-death analysis for those who 
died showed that mean survival was 1 year longer for those in ATTRm cohort (4.3 years 
+ 3.4) when compared to the ATTRwt cohort (3.0 years + 2.0). The disparity in survival 
and time-to-death for the ATTRm cohort versus the ATTRwt cohort could be influenced 
by disease extent. As such, it is possible that the ATTRwt cohort represented individuals 
with more advanced disease, but this distinction was not evaluated in this study. While 
this could be an area for future investigation, this study focused on the relationship 
between HRQOL and mortality within each cohort independently. 
 
For both cohorts, there were almost an equal proportion of individuals with PCS scores of 
< 35 as there were with scores > 35. However, for MCS, a greater proportion of 
individuals in both cohorts reported MCS > 35. Accordingly, 77% of the ATTRwt and 
78% of the ATTRm cohorts had individuals with scores > 35. This implies that while 
individuals in both cohorts experience low PCS, suggesting significant physical deficits, 
their mental health status did not appear to be affected to the same extent.  
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Table 3. Presentation of survival characteristics and PCS and MCS QOL scores <35 and 
> 35 in ATTRwt and ATTRm cohorts 
Feature ATTRwt cohort (n=133) 
ATTRm cohort 
(n=331) 
Age at completion of QOL, y mean (SD) 74.6 (6.0) 57.5 (13.9) 
Age at death, y mean (SD) 78.3 (5.7) 65.0 (11.5) 
Number of Deaths, N  (%) 72 (54%) 120 (36%) 
Survival, y mean (SD) 3.0  (2.2) 6.4 (5.4) 
Time-to-death (for those who died), y mean (SD) 3.0 (2.0) 4.3 (3.4) 
PCS   
<35, N (%) 65 (49%) 145 (44%) 
 > 35, N (%) 68 (51%) 186 (56%) 
MCS   
<35, N (%) 31 (23%) 73 (22%) 
> 35, N (%) 102 (77%) 258 (78%) 
 
Table 4 shows results, represented as hazard ratios from Cox proportional regression 
analysis examining the association between MCS, PCS and survival by cohort. All 
analyses were adjusted for age at time of SF-36 health survey completion, co-morbidities 
and sex. Only patients with complete data during the study period were included in the 
analysis. In the ATTRwt cohort (n=126), 70 deaths occurred and 44% were censored as 
alive at time of analysis. ATTRwt patients with PCS or MCS less than 35 had a 
significantly higher risk of death during follow-up than those with scores greater than or 
equal to 35 (HR=2.45, p=0.002 for PCS; HR 3.38 (p<0.0001) for MCS). In the ATTRm 
cohort (n=329), 120 deaths occurred and 64% were censored as alive. Within the 
ATTRm cohort, patients with PCS scores less than 35 also had a significantly higher risk 
of death during follow up than those with scores greater than 35 (HR=2.76, p<0.0001 for 
PCS). However, MCS within the same score dichotomization (< 35 vs. > 35) did not 
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demonstrate statistically significant increased risk of death during follow up (HR=1.38, 
p=0.13). 
 
Table 4. Cox proportional regression analysis in ATTRwt and ATTRm cohortsii 
 Hazard ratio p-value 
ATTRwt (n=126)*   
MCS < 35 vs. > 35 3.38 <0.0001 
PCS < 35 vs. > 35 2.45 0.002 
ATTRm (n=329)**   
MCS < 35 vs. > 35 1.38 0.13 
PCS < 35 vs. > 35 2.76 <0.0001 
 ii adjusted for diabetes mellitus, hypertension, hyperlipidemia, sex, and age at time of SF-
36 health survey. 
*(n=126, 70 deaths, 44% censored)  
**(n=329, 120 deaths, 64% censored)  
 
Figures 7 through 10 present the adjusted Kaplan-Meier curves estimating survival based 
on a dichotomization in PCS and MCS scores (<35 vs. >35). Survival curves for PCS and 
MCS < 35 are shown in red and > 35 in blue. In both cohorts, survival data was collected 
from time of SF-36 health survey completion to death, the endpoint of interest. Deaths 
are represented by downward steps in the Kaplan-Meier curves. Individuals alive at time 
of last follow-up or at the end of the study period examined were censored and 
represented as tick marks on the Kaplan-Meier curves. Overall, these data describe the 
survival function for both ATTRwt and ATTRm cohorts. 
 
Figure 7 shows that overall survival was significantly lower for patients with PCS <35 in 
the ATTRwt cohort when compared to those with PCS > 35 in the ATTRwt cohort (log 
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rank p < 0.0001). Figure 8 shows similar results for MCS <35 vs. > 35 within the 
ATTRwt cohort (log rank p < 0.0001).  
 
Figure 7. Kaplan-Meier curve for overall survival by PCS (< 35 (red) vs. > 35 (blue)) in 
ATTRwt cohort (n=133): 
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Figure 8. Kaplan-Meier curve for overall survival by MCS (< 35 (red) vs. > 35 (blue)) in 
ATTRwt cohort (n=133): 
 
 
 
Figures 9 and 10 present the adjusted Kaplan-Meier survival curves from time of SF-36 
health survey completion to death for the ATTRm cohort. Similar to overall survival 
trend seen in the ATTRwt population, Figure 9 shows that PCS <35 was significantly 
associated with lower survival when compared to PCS > 35 (log rank p < 0.0001). Figure 
10 shows that MCS <35 is also associated with lower survival, but not with the same 
level of significance (log rank p = 0.07).  
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Figure 9. Kaplan Meier Curve for overall survival by PCS scores (< 35 (red) vs. > 35 
(blue)) in ATTRm cohort (n=331): 
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Figure 10. Kaplan Meier Curve for overall survival by MCS (< 35 (red) vs. > 35 (blue)) 
in ATTRm cohort (n=331): 
 
 
 
Secondary analyses examining the relationship between PCS, MCS and clinical 
biomarkers of disease were also conducted and presented in Table 5. Using Spearman’s 
rank correlations, BNP and troponin I were inversely associated with both MCS (r= - 
0.24; p=0.01 and p=0.02, respectively) and PCS (r= - 0.29; p=0.002 and r= - 0.25; 
p=0.012, respectively) in the ATTRwt cohort. However, the strength of the association 
was greatest for PCS. In the ATTRm cohort, BNP and troponin I were also inversely 
associated with both MCS (r= - 0.16; p=0.03 and r= - 0.24; p=0.007, respectively) and 
PCS (r= - 0.50; p<0.0001 and r= - 0.41; p<0.0001, respectively). Overall, the association 
was greatest with PCS as the strength of a negative association measured by Spearman’s 
rank correlation increases as r approaches -1. Modified BMI did not appear to 
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significantly associate with MCS or PCS in the ATTRwt and ATTRm cohorts as 
evidenced by p-values greater than or equal to 0.05.   
 
Table 5. Spearman’s rank correlations between PCS, MCS and clinical biomarkers of 
disease in ATTRwt and ATTRm cohorts 
 MCS PCS 
ATTRwt cohort   
BNP (n=118) r= - 0.24  (p=0.01) r= - 0.29 (p=0.002) 
Troponin I (n=102) r= - 0.24 (p=0.02) r= - 0.25 (p=0.012) 
Modified BMI (n=116) r= - 0.08 (p=0.40) r= - 0.08 (p=0.40) 
ATTRm cohort   
BNP (n=179) r= - 0.16 (p=0.03) r= - 0.50 (p<0.0001) 
Troponin I (n=130) r= - 0.24 (p=0.007) r= - 0.41 (p<0.0001) 
Modified BMI (n=149) r=   0.10 (p=0.40) r=   0.16 (p=0.05) 
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SECTION 4. DISCUSSION 
 
ATTR is a progressive disease with devastating effects on functional health, often 
resulting in death. While other ATTR studies have shown that those with the greatest 
disease burden report the poorest HRQOL, no data systematically examined the effects of 
HRQOL on survival. In other chronic diseases, HRQOL has been shown to be a powerful 
predictor of survival and is often explored as an important functional health metric with 
the potential to guide disease management plans. This study appears to be the first study 
to examine the association between self-perceived physical and mental HRQOL, clinical 
biomarkers of major end organ function, and survival in the ATTR population.  
 
In this retrospective cohort study, ATTR disease significantly decreased an individual’s 
physical and mental quality of life. Mean PCS and MCS values were respectively 1.5 and 
0.5 SD below 50, the age and gender matched US population norm for both cohorts. This 
suggests that self-perceived physical HRQOL deficits experienced by the ATTRwt and 
ATTRm populations under study were more pronounced than self-perceived mental 
HRQOL deficits. Interestingly, overall survival varied by cohort during the follow-up 
time examined. The ATTRwt cohort exhibited an 18% higher mortality rate and shorter 
survival from time of SF-36 health survey completion to death when compared to the 
ATTRm cohort (3.0 years + 2.2 and 6.4 years + 5.4, respectively). Of those who died 
during the follow up period, mean survival was approximately 1 year longer in the 
ATTRm cohort (3.0 years + 2.0) than in the ATTRwt (4.3 years + 3.4). Despite similar 
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mean PCS and MCS observed for both cohorts, the higher mortality in the ATTRwt 
cohort could be explained by differences in disease severity. In support of this 
explanation, BNP and troponin I, both clinical biomarkers of amyloid cardiomyopathy, 
were significantly higher in the ATTRwt cohort indicating greater infiltrative heart 
disease involvement than in the ATTRm cohort. Although examining the association 
between disease extent and survival was not part of the study design, it is possible that 
survival differences observed were due to the presence of more individuals with 
advanced disease in the ATTRwt cohort than in the ATTRm cohort. 
 
Primary study analysis using Cox proportional hazards regression models revealed a 
significant association between HRQOL and survival. The correlations between PCS and 
MCS and survival varied significantly between the studied cohorts. In the ATTRwt 
population, both physical and mental HRQOL deficits predicted a significantly greater 
risk of death during follow-up. More specifically, PCS <35 associated with a 2.45 times 
greater risk of death compared to those with PCS > 35, and MCS <35 associated with a 
3.38 times greater risk of death compared to those with MCS > 35. The slightly greater 
risk of death associated with MCS < 35 when compared to PCS <35 was a finding unique 
to the ATTRwt cohort and could be reflective of a cohort comprised of individuals with 
more advanced disease. In the ATTRm cohort, only physical HRQOL deficits as 
evidenced by PCS <35 associated with a 2.76 times increased risk of death during the 
follow-up period examined. Similar magnitude mental HRQOL deficits (MCS <35) did 
not associate with an increased risk of death (HR=1.38, p=0.13).  
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These findings are further supported by Kaplan-Meier curves showing that MCS and PCS 
<35 significantly associate with lower survival when compared to MCS and PCS > 35 for 
both cohorts. The Kaplan-Meier curves also demonstrate a cohort-specific difference in 
follow-up time examined. In the ATTRm cohort, the follow-up time was longer than that 
of ATTRwt because of the greater number of deaths that were distributed over a longer 
period of time. Although matching follow-up times would have provided the ability to 
directly compare the two cohorts in a single survival analysis, it was not possible to do so 
without sacrificing power to explore the strength of the associations under study. 
Therefore, in order to capture all deaths observed during the overall 30-year study period, 
survival analyses were conducted in a cohort-dependent manner. Although, it is not 
possible to directly compare study results between ATTRwt and ATTRm cohorts, the 
survival analysis presented by this study show meaningful associations between survival 
and MCS and PCS in both cohorts that could have clinical value. 
 
The results of the Cox proportional hazards regression analysis and Kaplan-Meier curves 
presented by this study suggest that HRQOL assessed by the SF-36 health survey could 
be used as comprehensive predictor of survival in both ATTRwt and ATTRm 
populations. Overall, PCS and MCS were shown to be independent predictors of 
mortality. Given the physical deficits that result from progressive organ involvement, it 
would be expected that PCS was significantly associated with greater risk of death. 
However, in light of the significant associations between MCS and survival in the 
ATTRwt, caution should be taken when making inferences from HRQOL data, even 
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within the same subset of chronic disease. As such, these findings underscore the 
importance of evaluating HRQOL and survival in a disease-dependent manner in order to 
account for variations in disease processes that could impact overall health outcomes. In 
this way, the findings of this study are consistent with the observation across other 
diseases in that patients with a lower perception of their health status, by either PCS 
and/or MCS have a higher mortality.  
 
Secondary analyses using Spearman’s rank correlations showed significant inverse 
associations between HRQOL health scores and clinical biomarkers of disease in both 
cohorts. Both MCS and PCS inversely correlated with BNP and troponin I, however, the 
strength of the association was greatest for PCS, particularly in the ATTRm cohort. This 
suggests that HRQOL health status, specifically PCS, could be just as informative as 
clinical biomarkers of disease when examining disease status and prognosis in the ATTR 
population. However, this was an exploratory analysis and additional investigation is 
warranted to determine if HRQOL and clinical biomarkers of disease are interchangeable 
predicators of death. While preliminary, these findings support the clinical relevance of 
including HRQOL assessment as part of routine disease evaluation and management 
process.  
 
Demographic and clinical features presented by both study cohorts were consistent with 
expected differences observed in the general ATTRwt and ATTRm populations. As 
anticipated, the ATTRwt cohort was comprised of older males (74.6 years of age + 6.0) 
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with significant cardiac involvement as evidenced by elevated troponin I and BNP levels. 
The ATTRm cohort presented as a younger and more diverse population (57.5 years of 
age + 13.9). The mutation types presented (22% Thr60Ala, 19% Val30Met, 13% 
Val122Ile) were also consistent with those most commonly reported in the general 
ATTRm population. The fact that these study cohorts so closely represent anticipated 
ATTRwt and ATTRm population differences suggest that the associations between 
HRQOL, clinical biomarkers of disease and survival presented in this study are 
generalizable and have relevance to the ATTRwt and ATTRm populations worldwide. 
 
Overall, the results of this study have immediate clinical implications suggesting that 
HRQOL should be integrated into patient evaluations and treatment plans as a routinely 
collected measure of health status in the ATTR patient population. Whereas most 
clinicians are reticent to collect data they view as subjective, these results support 
HRQOL as an objective measurement of disease burden that have clinical relevancy. 
Reluctance to collect HRQOL data may stem from a lack of training in the interpretation 
of the results.64 Despite barriers to acceptance, the predictive value of HRQOL 
demonstrated in this study should not be overlooked as it could provide meaningful 
insights on disease prognosis that could help guide more informed disease management 
decisions. 
 
The ability to effectively manage disease is particularly imperative given the limited 
treatment options available for ATTR. Every effort must be made to proactively ensure 
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the best possible health outcomes. The association between HRQOL and survival shown 
by this study could not only help clinicians select optimal management plans from 
currently available ATTR treatment options, but could also assist in the development of 
novel therapies. When developing a drug, demonstrating improved perception of HRQOL 
is equally as important as treating the underlying disease. It is possible to find a drug that 
eradicates underlying disease, promotes extended survival, yet is associated with poor 
HRQOL.65 This suggests that there is an interplay between disease management, survival 
and HRQOL that must be considered. For this reason, the ability to quantify the effect of 
an intervention on HRQOL has become an important measure of treatment efficacy and 
has been integrated in the clinical trial plans of many drug development efforts.66  
 
The results of this study could be useful in the development of novel ATTR therapies as 
it establishes a relationship between HRQOL and mortality that could be representative 
of the general ATTR patient population. While the aim of drug development is to 
discover therapies that extend survival, the association between HRQOL and survival 
demonstrated by this study suggest that improved HRQOL is equally important and 
should be considered when assessing overall efficacy of a novel treatment. Researchers 
can use these results as a baseline measurement of what HRQOL and survival looks like 
in ATTR population. Overall, these data should be considered during the clinical trial 
development and evaluation process to ensure that an investigational therapy will not 
only effectively treat disease but also improve HRQOL.  
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4.1 Limitations 
A potential limitation of this study is the use of a pre-existing database to collect data of 
interest. Since all data were extracted from the BU Amyloidosis Center database, it was 
not always possible to cross-reference data reported for consistency and accuracy. Also, 
there were instances where data of interest were not captured and therefore could not be 
included in the analysis. Since this study examined HRQOL over a 30-year time interval, 
another limitation of this study included changes to routinely collected clinical data 
during the study period examined. For instance, clinical biomarkers of disease such as 
troponin I and BNP were not routinely collected until 2002. This means that patients 
presenting for evaluation before 2002 did not have these measures of interest recorded in 
the database and available for this study. Additionally, not all ATTR patients completed a 
SF-36 health survey at presentation to the BU Amyloidosis Center.  
 
These limitations reduced the overall sample size that could be included in the analysis, 
providing less power to determine differences and assess significance of the associations 
under study. Since significant associations were detected, it is unlikely that sample size 
affected study findings. However, it is possible that a larger sample size would have 
demonstrated associations the actual sample size was unable to detect.  
 
An additional study limitation was the inability to determine how long an individual had 
active disease before completion of the SF-36 health survey. This means that the 
population under study included individuals at all stages of disease, from those with mild 
 49 
symptoms to those with severe physical disability. If anything, it would be expected that 
such a limitation would lead to a bias towards the null. The fact that significant 
associations were detected despite this limitation suggest that study results may have 
been even stronger if it had been possible to stratify by disease severity.  
 
4.2 Future Directions 
 
Future directions include conducting a larger, prospective cohort study to examine the 
association between HRQOL and survival over time. This would involve the collection of 
multiple SF-36 health surveys as well as clinical measures of disease from an extensive 
patient population at predefined intervals. By examining HRQOL in such a way it would 
be possible to more precisely determine how HRQOL varies with respect to disease 
course. Furthermore, a prospective examination of HRQOL would not be reliant on 
historical data, thereby overcoming the current study’s limited ability to collect all data of 
interest. In such a way it would be possible to further investigate how the relative 
associations between clinical biomarkers of disease and HRQOL relate to survival. 
Additionally, it would also be possible to collect other pertinent data such as current 
treatment to further explore how HRQOL is affected by various interventions over time. 
A study of this magnitude would more robustly evaluate HRQOL as a clinically 
meaningful prognostic measure of survival in the ATTR population. In this way, such a 
future study would more deeply explore the importance of routinely collecting HRQOL 
as part of ATTR patient managed care plans, as well as its significance in guiding 
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individualized disease management plans that may ultimately lead to improved health 
outcomes
 51 
SECTION 5. CONCLUSION 
 
In conclusion, ATTR disease significantly decreased an individual’s physical and mental 
HRQOL. Low HRQOL, as described by the SF-36 health survey, was associated with an 
increased risk of death in a disease-specific manner within the ATTR population. PCS 
and MCS were shown to be independent predictors of mortality by cohort. In the 
ATTRwt cohort, patients with MCS and PCS <35 had a significantly greater risk of death 
during follow-up than those with MCS and PCS > 35. In the ATTRm cohort, PCS < 35 
also associated with a significantly greater risk of death than those with higher scores. 
However, similar magnitude deficits of MCS did not associate with increased risk of 
death. MCS and PCS correlated with BNP and troponin I in both cohorts, however, the 
strength of the association was greatest for PCS. Additional investigation is warranted to 
determine if HRQOL and clinical biomarkers of disease are interchangeable predicators 
of death.  
 
Furthermore, the study findings demonstrate the importance of including HRQOL 
measures in clinical disease prognostic efforts in order to better inform clinicians about 
disease extent and predict its overall impact on survival. While not a focus of this study, 
the associations between HRQOL and survival may also be relevant in the development 
of novel ATTR therapies and suggest that HRQOL should be included in drug efficacy 
assessments. Low HRQOL has been shown to correlate with survival in other diseases, 
but this study appears to be the first observational cohort study to demonstrate the 
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association in the ATTR population. Future studies confirming this association would 
further underscore the clinical benefit of systematically collecting HRQOL as part of 
routine ATTR patient care.  
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